Monoclonal antibody · Immune activation, directed at SLAMF7 · developed by Bristol Myers Squibb
Elotuzumab is a humanized IgG1 monoclonal antibody that binds SLAMF7, a protein expressed on myeloma cells, NK cells and plasma cells. It directly activates NK cells and mediates killing of myeloma cells through antibody-dependent cellular cytotoxicity and phagocytosis. It is studied in multiple myeloma, including refractory disease.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Mar 22, 2022). Read the full label for the exact wording, limitations and safety information.
Multiple MyelomaMyelomaRefractory Multiple Myeloma
Updated Nov 8, 2026. Something wrong or missing? Report it on the BMY page.
See BMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BMY catalysts and pipeline →